力生制药：11月13日召开董事会会议

Core Viewpoint - Lisheng Pharmaceutical (SZ 002393) announced the convening of its eighth board meeting on November 13, 2025, to discuss the appointment of the head of the audit and compliance department and other documents [1] Company Summary - Lisheng Pharmaceutical's revenue composition for the first half of 2025 is entirely from the pharmaceutical industry, accounting for 100.0% [1] - As of the report, Lisheng Pharmaceutical has a market capitalization of 5.7 billion yuan [1]